Dcis recurrence and invasive breast cancer
AssigneePrelude Corporation
InventorsTroy M. Bremer, Steven Paul Linke
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to methods and compositions relevant to the prediction that a subject with and/or after treatment for DCIS will experience a subsequent ipsilateral breast event that is a DCIS recurrence, an invasive breast cancer, both a DCIS recurrence and invasive cancer, or neither. The technology can assist one with how to treat such subjects.
Claims74
A method of analyzing a sample, the method comprising:
- analyzing a human DCIS tissue sample for PR, and either or both of:
- a) analyzing the sample for at least HER2 and SIAH2, or
- b) analyzing the sample for at least FOXA1.
A method of analyzing a sample, the method comprising:
- analyzing a human DCIS tissue sample for a level of at least SIAH2 and FOXA1.
A kit comprising:
- a FOXA1 probe;
- and
- a SIAH2 probe.
An antibody composition comprising:
- an isolated FOXA1 antibody;
- and
- an isolated SIAH2 antibody.
A method for prognosing a risk of an invasive breast cancer event in a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the DCIS sample for a level of at least PR, and at least either:
- a) analyzing the sample for at least HER2 and SIAH2, or
- b) analyzing the sample for at least FOXA1;
- and
- providing a prognosis based upon at least PR, HER2 and SIAH2 or based upon at least PR and FOXA1.
A method for prognosing a risk of an invasive breast cancer event in a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the sample for a level of at least SIAH2 and FOXA1;
- and
- prognosing the subject as having an elevated risk of an invasive breast cancer based upon the level of at least SIAH2 and FOXA1.
A method for prognosing a risk of an invasive breast cancer event in a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the sample for:
- a) PR, HER2, and SIAH2, or
- b) PR and FOXA1;
- and
- prognosing the subject as having an elevated risk of an invasive breast cancer event when at least one of:
- a) PR−, HER2−, and SIAH2−,
- b) PR+, FOXA1+, or
- c) PR+, FOXA1−, and Ki67+.
A method for treating a subject at risk of having an invasive breast cancer, the method comprising:
- providing a subject having DCIS, wherein the subject has a DCIS that is at least one of:
- a) PR−, HER2−, and SIAH2−,
- b) PR+, FOXA1+, or
- c) PR+, FOXA1−, and Ki67+;
- and
- administering to the subject a therapy that is more aggressive than standard of care for DCIS.
A method of analyzing a sample, the method comprising:
- providing a DCIS sample from a subject having DCIS;
- 1. analyzing the DCIS sample for SIAH2, and analyzing the DCIS sample for at least one of HER2, PR, FOXA1, or any combination thereof;
- or
- 2. analyzing the DCIS sample for FOXA1 and PR.
A method for prognosing a risk of a subsequent DCIS event in a subject, said method comprising:
- providing a DCIS sample from a subject;
- analyzing the sample for at least one of:
- a) SIAH2 and FOXA1,
- b) SIAH2 and at least one of i) PR and ii) HER2, or
- c) SIAH2 and post-menopausal status;
- and
- d) PR and FOXA1
- prognosing the subject as having an elevated risk of a DCIS event when at least one of:
- a) SIAH2+ and FOXA1+,
- b) SIAH2+ and HER2+ or PR−,
- SIAH2+ and post-menopausal, or
- PR+ and FOXA1−,
- is present in the DCIS sample.
A method for treating a subject at risk of having a DCIS recurrence, the method comprising:
- providing a subject having DCIS, wherein the subject has a DCIS that is at least one of:
- a) i) SIAH2+ and FOXA1+
- b) SIAH2+ and HER2+ or PR−;
- c) SIAH2+ and post-menopausal status;
- or
- d) PR+ and FOXA1−,
- administering to the subject a more aggressive therapy than standard of care for a single DCIS event.
A method of detecting gene expression in a DCIS sample, comprising detecting expression of at least SIAH2 and FOXA1 in the DCIS sample obtained from a subject with DCIS.
The method of claim 54, wherein expression of the at least at least SIAH2 and FOXA1 is measured by real time quantitative polymerase chain reaction or microarray analysis.
A solid support comprising probes or antibodies specific for at least SIAH2 and FOXA1.
The solid support of claim 57, wherein the probes or antibodies consists essentially of probes or antibodies specific for the prediction of DCIS or invasive breast cancer in a subject who has DCIS.
The method of claim 63, wherein the DCIS sample is further analyzed for HER2.
The method of claim 64, wherein the DCIS sample is further analyzed for COX-2.
The method of claim 65, wherein the DCIS sample is further analyzed for Ki67.
The method of claim 66, wherein the DCIS sample is further analyzed for p16.
The method of claim 72, wherein a therapy appropriate to reduce a risk of DCIS recurrence comprises at least one of surgical resection, radiation therapy, anti-hormone therapy.
A method for treating a subject, the method comprising:
- providing a subject having DCIS, wherein the subject has a DCIS that is none of:
- a) PR−, HER2−, and SIAH2−,
- b) PR+, FOXA1+, or
- d) PR+, FOXA1−, and Ki67+;
- and
- administering to the subject a therapy that is less aggressive than standard of care for DCIS.
Dependencies are inferred from the claim text.